Loading clinical trials...
Loading clinical trials...
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Conditions
Interventions
Clazakizumab
Physiologic saline solution
Locations
142
United States
University of Alabama at Birmingham (UAB) - University of Alabama Hospital (UAB Hospital)
Birmingham, Alabama, United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
Keck Medical Center Of USC
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
UCLA Kidney Transplant Research Program
Los Angeles, California, United States
University of California Davis Medical Center
Sacramento, California, United States
Start Date
October 14, 2019
Primary Completion Date
April 8, 2024
Completion Date
April 8, 2024
Last Updated
July 23, 2025
NCT06685757
NCT05004493
NCT04561986
NCT07316829
NCT03719339
NCT03380962
Lead Sponsor
CSL Behring
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions